WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.32/34

Afatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC


Vera Hirsh, Eng-Huat Tan, Yi-Long Wu, Lecia V. Sequist, Caicun Zhou, Martin Schuler, Sarayut L. Geater, Tony Mok, Cheng-Ping Hu, Nobuyuki Yamamoto, Jifeng Feng, Kenneth O’Byrne, Shun Lu, Yunchao Huang, Martin Sebastian, Isamu Okamoto, Nicolas Dickgreber, Riyaz Shah, Michael Palmer, Angela Märten, Dan Massey, Carl Samuelsen, James Chih-Hsin Yang

Related Material

Learn more about the science behind this poster in the videos, papers and other materials below.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang JC-H, et al. Ann Oncol. 2016;27:2103-10.

LUX-Lung 3 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

Sequist LV, et al. J Clin Oncol. 2013;31:3327–34

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu Y-L, et al. Lancet Oncol. 2014;15:213–22.